Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H4 | Q96RI1 | 2/20 | 0.85 |
| ▸ | CNR1 | P21554 | 10/20 | 0.37 |
| ▸ | CNR2 | P34972 | 9/20 | 0.37 |
| ▸ | FAAH | O00519 | 4/20 | 0.37 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.37 |
| ▸ | MGLL | Q99685 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | USP14 | P54578 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1712085 | 0.98 | NR1H4 (0.82) | NR1H4CNR1CNR2FAAHENPP2 | |
| SCHEMBL2382276 | 0.98 | NR1H4 (0.82) | NR1H4CNR1CNR2FAAHENPP2 | |
| SCHEMBL2382652 | 0.92 | NR1H4 (1.00) | NR1H4CNR1CNR2FAAHENPP2 | |
| SCHEMBL2381696 | 0.90 | NR1H4 (0.97) | NR1H4CNR1CNR2FAAHENPP2 | |
| SCHEMBL1712077 | 0.90 | NR1H4 (0.97) | NR1H4CNR1CNR2FAAHENPP2 | |
| SCHEMBL2381623 | 0.86 | NR1H4 (0.66) | NR1H4ENPP2 | |
| SCHEMBL1712051 | 0.85 | NR1H4 (0.64) | NR1H4 | |
| SCHEMBL1712564 | 0.85 | NR1H4 (0.62) | NR1H4CNR1CNR2FAAHMGLL | |
| SCHEMBL1712415 | 0.84 | NR1H4 (0.61) | NR1H4CNR1CNR2FAAHMGLL | |
| SCHEMBL2382413 | 0.81 | NR1H4 (0.59) | NR1H4CNR1CNR2FAAHENPP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2550254-A1 | CYCLOPENTYL - AND CYCLOHEPTYLPYRAZOLES AS FXR MODULATORS | F. Hoffmann-La Roche AG (CH) | 2013-01-30 | — | — | EP | claimed |
| US-8252826-B2 | Cyclopentyl- and cycloheptylpyrazoles | HOFFMANN-LA ROCHE INC. (US) | 2012-08-28 | — | — | US | claimed |
| US-20110237628-A1 | CYCLOPENTYL- AND CYCLOHEPTYLPYRAZOLES | F. HOFFMANN-LA ROCHE AG (CH) | 2011-09-29 | — | — | US | claimed |
| WO-2011117163-A1 | CYCLOPENTYL - AND CYCLOHEPTYLPYRAZOLES AS FXR MODULATORS | F. HOFFMANN-LA ROCHE AG (CH) | 2011-09-29 | — | — | WO | claimed |
| EP-2550254-A1 | CYCLOPENTYL - AND CYCLOHEPTYLPYRAZOLES AS FXR MODULATORS | F. Hoffmann-La Roche AG (CH) | 2013-01-30 | — | — | EP | disclosed |
| US-8252826-B2 | Cyclopentyl- and cycloheptylpyrazoles | HOFFMANN-LA ROCHE INC. (US) | 2012-08-28 | — | — | US | disclosed |
| US-8252826-B2 | Cyclopentyl- and cycloheptylpyrazoles | HOFFMANN-LA ROCHE INC. (US) | 2012-08-28 | — | — | US | disclosed |
| US-8252826-B2 | Cyclopentyl- and cycloheptylpyrazoles | HOFFMANN-LA ROCHE INC. (US) | 2012-08-28 | — | — | US | disclosed |
| US-20110237628-A1 | CYCLOPENTYL- AND CYCLOHEPTYLPYRAZOLES | F. HOFFMANN-LA ROCHE AG (CH) | 2011-09-29 | — | — | US | disclosed |
| US-20110237628-A1 | CYCLOPENTYL- AND CYCLOHEPTYLPYRAZOLES | F. HOFFMANN-LA ROCHE AG (CH) | 2011-09-29 | — | — | US | disclosed |
| US-20110237628-A1 | CYCLOPENTYL- AND CYCLOHEPTYLPYRAZOLES | F. HOFFMANN-LA ROCHE AG (CH) | 2011-09-29 | — | — | US | disclosed |
| WO-2011117163-A1 | CYCLOPENTYL - AND CYCLOHEPTYLPYRAZOLES AS FXR MODULATORS | F. HOFFMANN-LA ROCHE AG (CH) | 2011-09-29 | — | — | WO | disclosed |
| WO-2011117163-A1 | CYCLOPENTYL - AND CYCLOHEPTYLPYRAZOLES AS FXR MODULATORS | F. HOFFMANN-LA ROCHE AG (CH) | 2011-09-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110237628-A1 | CYCLOPENTYL- AND CYCLOHEPTYLPYRAZOLES | CYP1B1, CYP1A1, CYP4F3 | NR1H4 644/4885CNR1 19/4885CNR2 51/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.